论文部分内容阅读
近日在意大利举办的第15届国际内分泌学大会暨第14届内分泌学会议欧洲代表大会(ICE/ECE)上公布的数据显示,多受体靶向生长抑素类似物(SSA)——pasireotide长效缓释制剂(LAR)的完全生物化学控制率[即用药后体内生长激素(GH)水平低
Recent data published at the 15th International Congress of Endocrinology and the 14th European Conference on Endocrinology (ICE / ECE) in Italy showed that the receptor-targeted somatostatin analogues (SSA) The complete biochemical control of a sustained-release formulation (LAR) [ie, low levels of growth hormone (GH) in the body after administration